Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: Therapeutic potential for migraine

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 2, 2007, Pages 564-572

  Peeters, Magali ^a,b   Gunthorpe, Martin J ^a   Strijbos, Paul J L M ^a,c   Goldsmith, Paul ^a   Upton, Neil ^a   James, Michael F ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b CNRS   (France)

^c Johnson and Johnson Pharmaceutical R and D ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; DIZOCILPINE; ISOFLURANE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROPRANOLOL DERIVATIVE; TRAXOPRODIL; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL CARBON DIOXIDE TENSION; ARTICLE; BLOOD FLOW; BRAIN CORTEX; CONTROLLED STUDY; CORE TEMPERATURE; DOSE RESPONSE; DRUG EFFECT; GENERAL ANESTHESIA; MALE; MIGRAINE; NONHUMAN; OXYGEN TENSION; PH MEASUREMENT; PRESSURE; PRIORITY JOURNAL; SPREADING CORTICAL DEPRESSION;

ANIMALS; CEREBROVASCULAR CIRCULATION; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MEMANTINE; MIGRAINE DISORDERS; OXYGEN; PHENOLS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SPREADING CORTICAL DEPRESSION;

EID: 34247179646     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.117101     Document Type: Article

References (43)

1. Afridi SK, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowiak RSJ, and Goadsby PJ (2005) A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 128:932-939.
2. Anderson TR and Andrew RD (2002) Spreading depression: imaging and blockade in the rat neocortical brain slice. J Neurophysiol 88:2713-2725.
3. Ayata C, Jin H, Kudo C, Dalkara T, and Moskowitz MA (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59:652-661.
4. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, and Moskowitz MA (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8:136-142.
5. Bowyer SM, Mason KM, Moran JE, Tepley N, and Mitsias PD (2005) Cortical hyperexcitability in migraine patients before and after sodium valproate treatment. J Clin Neurophysiol 22:65-67.
6. Brown EA, Griffiths R, Harvey CA, and Owen DAA (1986) Pharmacological studies with SK&F 93944 (temalastine), a novel histamine H1-receptor antagonist with negligible ability to penetrate the central nervous system. Br J Pharmacol 87:569-578.
7. Bullock R (2006) Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Alzheimer Dis Assoc Disord 20:23-29.
8. Cammarata D and Krusz JC (2005) Memantine: novel mechanism for migraine and headache prophylaxis. Headache 45:820.
9. Chazot PL (2004) The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr Med Chem 11:389-396.
10. Chazot PL, Lawrence S, and Thompson CL (2002) Studies on the subtype selectivity of CP-101,606: evidence for two classes of NR2B-selective NMDA receptor antagonists. Neuropharmacology 42:319-324.
11. Chen H-SV and Lipton SA (2006) The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 97:1611-1626.
12. Czapinski P, Blaszczyk B, and Czuczwar SJ (2005) Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 5:3-14.
13. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, and Quack G (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci Biobehav Rev 21:455-468.
14. Dingledine R, Borges K, Bowie D, and Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51:7-62.
15. Faria LC and Mody I (2004) Protective effect of ifenprodil against spreading depression in the mouse entorhinal cortex. J Neurophysiol 92:2610-2614.
16. Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E, Heitz MP, and Kemp JA (1997) Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther 283:1285-1292.
17. Gallo V and Ghiani CA (2000) Glutamate receptors in glia: new cells, new inputs and new functions. Trends Pharmacol Sci 21:252-258.
18. 3H]ifenprodil binding to recombinant human NR1a/NR2B receptors compared with native receptors in rodent brain membranes. J Neurochem 75:2455-2463.
19. James MF and LunnonMW(2005) Making progress in the acute treatment of stroke: preclinical and clinical challenges for pharmaceutical medicine. Int J Pharm Med 19:77-88.
20. Kaube H, Herzog J, Kaufer T, Dichgans M, and Diener HC (2000) Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 55:139-141.
21. Kew JN, Trube G, and Kemp JA (1996) A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J Physiol (Lond) 497:761-772.
22. Kornhuber J and Weller M (1997) Psychotogenicity and N-methyl- D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41:135-144.
23. Kunkler PE and Kraig RP (2003) Hippocampal spreading depression bilaterally activates the caudal trigeminal nucleus in rodents. Hippocampus 13:835-844.
24. Lauritzen M and Hansen AJ (1992) The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression. J Cereb Blood Flow Metab 12:223-229.
25. Loftis JM and Janowsky A (2003) The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther 97:55-85.
26. Marrannes R, Willems R, De Prins E, and Wauquier A (1988) Evidence for a role of the (N-methyl-D-aspartate) receptor in cortical spreading depression in the rat. Brain Res 457:226-240.
27. Massieu L, Thedinga KH, McVey M, and Fagg GE (1993) A comparative analysis of neuroprotective properties of competitive and uncompetitive N-methyl-D-aspartate receptor antagonists in vivo: implication for the process of excitotoxic degeneration and its therapy. Neuroscience 55:883-892.
28. Menniti FS, Pagnozzi MJ, Butler P, Chenard BL, Jaw-Tsai SS, and White WF (2000) CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents. Neuropharmacology 39:1147-1155.
29. Moskowitz MA, Nozaki K, and Kraig RP (1993) Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 13:1167-1177.
30. Murray F, Kennedy J, Hutson PH, Elliot J, Huscroft I, Mohnen K, Russell MGN, and Grimwood S (2000) Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro. Eur J Pharmacol 397:263-270.
31. Obrenovitch TP and Zilkha E (1995) High extracellular potassium, and not extracellular glutamate, is required for the propagation of spreading depression. J Neurophysiol 73:2107-2714.
32. Obrenovitch TP and Zilkha E (1996) Inhibition of cortical spreading depression by L-701,324, a novel antagonist at the glycine site of the N-methyl-D-aspartate receptor complex. Br J Pharmacol 117:931-937.
33. Parsons CG, Danysz W, and Quack G (2000) Memantine and the amino-alkylcyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists - in vitro characterisation. Amino Acids 19:157-166.
34. Perin-Dureau F, Rachline J, Neyton J, and Paoletti P (2002) Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J Neurosci 22:5955-5965.
35. Porter RHP and Greenamyre JT (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64:614-623.
36. Sanchez-del-rio M, Reuter U, and Moskowitz MA (2006) New insights into migraine pathophysiology. Curr Opin Neurol 19:294-298.
37. Sheinin A, Nahum-Levy R, Shavit S, and Benveniste M (2002) Specificity of putative partial agonist, 1-aminocyclopropanecarboxylic acid, for rat N-methyl-D-aspartate receptor subunits. Neurosci Lett 317:77-80.
38. Smith JM, Bradley DP, James MF, and Huang CL-H (2006) Physiological studies of cortical spreading depression. Biol Rev 81:457-481.
39. Sorensen R and Jenson M (2005) Memantine, a treatment for migraine: a prospective open-label trial; in 21st Annual Meeting of the American Academy of Pain Medicine; 2005 Feb 23-27; Palm Springs, CA. Abstract 101, American Academy of Pain Medicine, Glenview, IL.
40. Strong AJ, Fabricius M, Boutelle MG, Hibbins SJ, Hopwood SJ, Jones R, Parkin MC, and Lauritzen M (2002) Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke 33:2738-2743.
41. Tatlisumak T, Takano K, Meiler MR, and Fisher M (1998) A glycine site antagonist, ZD9379, reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Stroke 29:190-195.
42. Willette RN, Lysko PG, and Sauermelch CF (1994) A comparison of (+)SK&F 10047 and MK-801 on cortical spreading depression. Brain Res 648:347-351.
43. Yurkewicz L, Weaver J, Bullock MR, and Marshall LF (2005) The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma 22:1428-1443.